Displaying 1121 - 1140 of 1327
FTC, Spanish Data Protection Agency Working Together to Fight Illegal Spam
Teva Pharmaceuticals USA, Inc. v. Pfizer, Inc.
Cephalon, Inc., and CIMA Labs, Inc.
The consent order settled charges that Cephalon's proposed acquisition of Cima Labs, Inc. would allow Cephalon to continue its monopoly in the United States market for drugs that eliminate or reduce the spikes of severe pain that chronic cancer patients experience. The consent order required Cephalon to grant Barr Laboratories, Inc. a fully paid, irrevocable license to make and sell a generic version of Cephalon's breakthrough cancer pain drug, Actiq, in the United States.
Announced Action for December 28, 2004
Updated: FTC to Co-Sponsor Town Meetings on Patent System Reform
Peer-to-Peer File-Sharing Technology: Consumer Protection and Competition Issues
Statement of the Federal Trade Commission Regarding the Decision to Close Its Investigation into the Conduct of Akzo Nobel, NV and Its Organon Subsidiary
FTC to Host Two-day Peer-to-peer File-sharing Workshop
Phillips, Edward H. v. AWH Corporation, Hopeman Brothers, Inc. and Lofton Corporation
Announced Actions for September 3, 2004
Itron, Inc., and Schlumberger Electricity, Inc., In the Matter of
The consent order, designed to preserve competition in the market for the manufacture and sale of mobile radio frequency automatic meter reading technologies for electric utilities in the United States, permitted Itron's $255 million acquisition of Schlumberger Electricity, Inc. The consent order requires Itron to grant a royalty-free, perpetual, and irrevocable license to Hunt Technologies, Inc., creating an effective competitor in this market that allows utility companies and others to gather electric consumption data automatically and remotely from electricity meters.
FTC Unveils New E-mail Address for Deceptive Spam: Spam@uce.gov
Andrx Pharmaceuticals, Inc. v. Kroger Co
FTC Reinstates Complaint of Unfair Methods of Competition Against Unocal
Consumer Protection Cops Join Forces to Fight Illegal Spam Six Agencies on Three Continents Will Leverage Law Enforcement Efforts
Bristol-Myers Squibb Company, In the Matter of
Bristol-Myers Squibb Company (BMS) settled charges that it engaged in illegal business practices to delay the entry of three low price generic pharmaceuticals that would be in direct competition with three of its branded drugs. The complaint alleged that BMS purposely made wrongful listings in the Orange Book of the U.S. Food & Drug Administration and that it also paid a potential competitor over $70 million to delay the entry of its generic drug. The three drugs involved in the complaint are: Taxol (containing the active ingredient paclitaxel) – used to treat ovarian, breast, and lung cancers; Platinol (containing the active ingredient cisplatin) – used for the treatment of various forms of cancer; and BuSpar (containing the active ingredient buspirone) – used to manage anxiety disorders. To prevent recurrence of Bristol's pattern of alleged improper listings, the consent order eliminates Bristol's ability to obtain a 30-month stay on later-listed patents. By denying Bristol the benefit of the 30-month stay on later-listed patents, the order would reduce Bristol's incentive to engage in improper behavior before the PTO and the FDA to obtain and list a patent for the purpose of obtaining an unwarranted automatic 30-month stay.
Prepared Statement of the Federal Trade Commission On Spyware
Monitoring Software on Your PC: Spyware, Adware and Other Software
Displaying 1121 - 1140 of 1327